Gregory Piazza, MD, MS, discusses the results of ROXI-CATH, which illustrated amrecibart’s and cenvacibart’s efficacy in reducing thrombosis events without increasing bleeding.
Gregory Piazza, MD, MS
Advertisement
Gregory Piazza, MD, MS, is a cardiovascular medicine specialist at Brigham and Women’s Hospital and an associate professor of medicine at Harvard Medical School.
Articles by Gregory Piazza, MD, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Lp(a) HORIZON Shows Pelacarsen Lowers Lp(a) 78% But Not Cardiovascular Events
2
Cannabis Use Tied to Higher Odds of Stroke, Cardiovascular Disease
3
ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD
4
Fazirsiran Reduces Liver Z-AAT Burden in AATD Liver Disease
5